Literature DB >> 21094132

Galectin-3 binding protein promotes cell motility in colon cancer by stimulating the shedding of protein tyrosine phosphatase kappa by proprotein convertase 5.

Yong-Sam Kim1, Jee-Ae Jung, Hyun-Jung Kim, Yeong Hee Ahn, Jong Shin Yoo, Sejeong Oh, Changhee Cho, Hyang-Sook Yoo, Jeong-Heon Ko.   

Abstract

It has previously been reported that shedding of the PTPκ ectodomain drives enhanced motility of colon cancer cells. Herein, we provide mechanism underlying the regulation of PTPκ shedding by galectin-3 binding protein. PTPκ was inarguably scissored by the processed form of proprotein convertase 5 (subtilisin/kexin type 5), and galectin-3 binding protein which is over-produced in colon cancer cells and tissues contributed to increased cancer cell motility by acting as a negative regulator of galectin-3 at the cell surface. The high expression ratio of galectin-3 binding protein to galectin-3 was clinically correlated to lymphatic invasion. These results suggest that galectin-3 binding protein may be a potential therapeutic target for treatment of, at least, colon cancer patients with high expression of galectin-3 binding protein. Copyright Â
© 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21094132     DOI: 10.1016/j.bbrc.2010.11.071

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma.

Authors:  Ling Xie; Wen-Kai Ni; Xu-Dong Chen; Ming-Bing Xiao; Bu-You Chen; Song He; Cui-Hua Lu; Xiao-Yan Li; Feng Jiang; Run-Zhou Ni
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-25       Impact factor: 4.553

2.  High-throughput screening of tumor metastatic-related differential glycoprotein in hepatocellular carcinoma by iTRAQ combines lectin-related techniques.

Authors:  Xue Qin; Qiaopei Chen; Chun Sun; Cun Wang; Qiliu Peng; Li Xie; Yinkun Liu; Shan Li
Journal:  Med Oncol       Date:  2013-01-06       Impact factor: 3.064

Review 3.  Receptor-type tyrosine phosphatase ligands: looking for the needle in the haystack.

Authors:  Alma N Mohebiany; Roman M Nikolaienko; Samuel Bouyain; Sheila Harroch
Journal:  FEBS J       Date:  2012-07-05       Impact factor: 5.542

Review 4.  Regulation of development and cancer by the R2B subfamily of RPTPs and the implications of proteolysis.

Authors:  Sonya E L Craig; Susann M Brady-Kalnay
Journal:  Semin Cell Dev Biol       Date:  2014-09-16       Impact factor: 7.727

Review 5.  Receptor protein tyrosine phosphatases and cancer: new insights from structural biology.

Authors:  Roman M Nikolaienko; Boadi Agyekum; Samuel Bouyain
Journal:  Cell Adh Migr       Date:  2012-07-01       Impact factor: 3.405

6.  The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

7.  An Impermeant Ganetespib Analog Inhibits Extracellular Hsp90-Mediated Cancer Cell Migration that Involves Lysyl Oxidase 2-like Protein.

Authors:  Jessica McCready; Daniel S Wong; Joseph A Burlison; Weiwen Ying; Daniel G Jay
Journal:  Cancers (Basel)       Date:  2014-04-30       Impact factor: 6.639

Review 8.  Genetic alterations of protein tyrosine phosphatases in human cancers.

Authors:  S Zhao; D Sedwick; Z Wang
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

Review 9.  The Role of Galectins in Cervical Cancer Biology and Progression.

Authors:  Lufang Wang; Yanyan Zhao; Yanshi Wang; Xin Wu
Journal:  Biomed Res Int       Date:  2018-05-08       Impact factor: 3.411

10.  Comprehensive genomic characterization of cutaneous malignant melanoma cell lines derived from metastatic lesions by whole-exome sequencing and SNP array profiling.

Authors:  Ingrid Cifola; Alessandro Pietrelli; Clarissa Consolandi; Marco Severgnini; Eleonora Mangano; Vincenzo Russo; Gianluca De Bellis; Cristina Battaglia
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.